Immune-inflammatory processes and gene therapeutics

Summary

The Immune-inflammatory Processes and Gene Therapy research group carries out translational research with a primary focus on the molecular basis of immune-inflammatory processes and related complex diseases. Its aim is to promote relevant, high-quality research into inflammation and to provide an optimal environment for training young researchers.

88 Publications

Strategic lines

Identification and characterisation of new immunomodulatory proteins and evaluation of their relevance and therapeutic potential in immune-mediated inflammatory diseases.
Analysis of new diagnostic/prognostic biomarkers in acute and chronic inflammatory pathologies.
Oxidative stress in epithelial cells of the respiratory pathways.
Inflammatory molecular mechanisms.
Molecular basis of urogenital diseases and male infertility. The immune response as a potential etiological factor of complex diseases.

Selected Publications

Checa,J;Fiol,P;Guevara,M;Aran,JM, TNFRSF1B Signaling Blockade Protects Airway Epithelial Cells from Oxidative Stress, Antioxidants, 2024;13(3):doi:10.3390/antiox13030368
Ferre-Giraldo A, Castells M, Sánchez-Herrero JF, López-Rodrigo O, de Rocco-Ponce M, Bassas L, Vigués F, Sumoy L, Larriba S. Semen sEV tRF-based models increase non-invasive prediction accuracy of clinically significant prostate cancer among patients with moderately altered PSA levels. Int J Mol Sci. 2024 Sep 20;25(18):10122. doi: 10.3390/ijms251810122
Larriba,S;Sánchez Herrero,JF;Pluvinet,R;López Rodrigo,O;Bassas,L;Sumoy,L, Seminal extracellular vesicle sncRNA sequencing reveals altered miRNA/isomiR profiles as sperm retrieval biomarkers for azoospermia, Andrology, 2023;12(1):137-156, doi:10.1111/andr.13461
Serrano,I;Luque,A;Ruiz Cerulla,A;Navas,S;Blom,AM;de Córdoba,SR;Fernández,FJ et al, C4BP(ß-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients, Pharmacol. Res., 2023;197106948-106948, doi:10.1016/j.phrs.2023.106948,
Serrano I, Luque A, Mitjavila F, Blom AM, Rodríguez de Córdoba S, Vega MC, Torras J, Aran JM. The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity. Front. Immunol. 2022;13883743-883743. doi:10.3389/fimmu.2022.883743.

Selected Projects

CI24-30620. Heptammune: a first-in-class biologic immunomodulator against autoimmune inflammatory bowel disease. FUNDACIÓ “LA CAIXA”. Budget: 501.000€. 2024-2026. PI: ARAN PERRAMON, JOSE MARIA.
PI23/00285. Caracterización de Heptammune, un nuevo inmunomodulador biológico para controlar la hiperinflamación y la inmunidad entrenada desadaptada en enfermedades autoinmunes. Instituto de Salud Carlos III (ISCIII). Budget: 252.500€. 2024-2026. PI: ARAN PERRAMON, JOSE MARIA.
SLT036/24/000006. Desenvolupament i validació d’Heptammune, un innovador fàrmac biològic immunomodulador capaç de resoldre la inflamació en la malaltia inflamatòria intestinal. Generalitat de Catalunya. Budget: 199.892€. 2024-2026. PI: ARAN PERRAMON, JOSE MARIA.
PI20/00464. Caracterización, potencial diagnóstico y terapeútico de un nuevo inmunomodulador biológico para el tratamiento de enfermedades autoinmunes.. Instituto de Salud Carlos III (ISCIII). Budget: 171.820€. 2021-2025. PI: ARAN PERRAMON, JOSE MARIA.
2021 INNOV 00020. PurPose Biotherapeutics: first-in-class metabolic modulators against autoimmune diseases. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 84.000,06€. 2022-2024. PI: ARAN PERRAMON, JOSE MARIA.

Technology transfer

Active Patents:

PAT10- ""Compositions and methods for immunomodulation""
OWNERSHIP:100% IDIBELL
REQUEST No.: EP11382240
PRIORITY COUNTRY: European Union
PRIORITY DATE: 15/07/11
PCT APPLICATION: PCT/EP2012/063932 (16/07/12)
IP: Josep Maria Aran
Currently in national phases in Europe (Switzerland, Germany, Denmark, Spain, France, UK, Italy, Norway, Poland, Sweden, Turkey), Japan, USA, Australia and Canada.
Patent granted in all these countries:"
PAT62-COMPUESTOS BASADOS EN C4BP PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOLÓGICAS
EP17382187.7
IP: J M Aran
ownership: 100% IDIBELL
06/07/2017
PAT76- “Compounds for immunomodulation""
INVENTORS: (by order of signature): Aran, J.M., Luque, A., Serrano, I.
OWNERSHIP:100% IDIBELL
REQUEST No.: EP19382910
PRIORITY COUNTRY: European Union
PRIORITY DATE: 17/10/19
PAT090-Compounds for treating diseases
INVENTORS: (by order of signature): Aran, J.M., Luque, A., Serrano, I.
OWNERSHIP:100% IDIBELL
PRIORITY COUNTRY: European Union
PRIORITY DATE: 15/02/2024
REQUEST: EP24382150.1